The information presented in this article comes from HighTech Business Decisions' ("HTBD") latest report, Biopharmaceutical Contract Manufacturing; Best Practices Pricing Study 2011.
In HTBD's study, the biotechnology and pharmaceutical companies provided the prices they paid for the contract production of their biopharmaceuticals.
The price details from these production campaigns come from HTBD's current price study along with its past 2008 study.